BlackRock Discloses Significant Passive Stake in Pliant Therapeutics
Ticker: PLRX · Form: SC 13G · Filed: Jan 25, 2024 · CIK: 1746473
| Field | Detail |
|---|---|
| Company | Pliant Therapeutics, Inc. (PLRX) |
| Form Type | SC 13G |
| Filed Date | Jan 25, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a big passive stake in Pliant Therapeutics, signaling institutional interest.**
AI Summary
BlackRock Inc., a major asset manager, reported on January 25, 2024, that it holds a significant stake in Pliant Therapeutics, Inc. (PLRX) as of December 31, 2023. This filing indicates BlackRock's passive ownership, meaning they are not seeking to influence company management. For investors, this signals that a large, institutional investor sees value in PLRX, potentially lending credibility to the stock, but it doesn't imply any immediate operational changes or strategic moves.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a notable position in Pliant Therapeutics, which can be a vote of confidence for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally doesn't introduce new risks to the company or its stock.
Analyst Insight
An investor might view BlackRock's passive stake as a positive signal, suggesting institutional confidence in Pliant Therapeutics, but should conduct further due diligence on the company's fundamentals and pipeline rather than solely relying on this filing.
Key Players & Entities
- BlackRock Inc. (company) — the reporting person, a major asset manager
- PLIANT THERAPEUTICS, INC. (company) — the subject company whose shares are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 25, 2024 (date) — the filing date of the SC 13G
FAQ
Who filed this SC 13G statement?
This SC 13G statement was filed by BlackRock Inc., a company with the Central Index Key 0001364742, located at 50 Hudson Yards, New York, NY 10001.
Which company's securities are the subject of this filing?
The securities that are the subject of this filing belong to PLIANT THERAPEUTICS, INC., identified by the Central Index Key 0001746473, with its business address at 260 Littlefield Avenue, South San Francisco, CA 94080.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of PLIANT THERAPEUTICS INC. is 729139105.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as stated on the cover page of the filing.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed pursuant to Rule 13d-1(b), as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 25, 2024 regarding PLIANT THERAPEUTICS, INC. (PLRX).